Compare CIEN & BSX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CIEN | BSX |
|---|---|---|
| Founded | 1992 | 1979 |
| Country | United States | United States |
| Employees | 9080 | N/A |
| Industry | Telecommunications Equipment | Medical/Dental Instruments |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 60.7B | 65.8B |
| IPO Year | 1996 | 2010 |
| Metric | CIEN | BSX |
|---|---|---|
| Price | $448.31 | $51.57 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 14 | 22 |
| Target Price | ★ $382.69 | $93.18 |
| AVG Volume (30 Days) | 2.1M | ★ 18.4M |
| Earning Date | 06-04-2026 | 04-22-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 46.55 | ★ 55.20 |
| EPS | ★ 2.52 | 1.51 |
| Revenue | $4,769,507,000.00 | ★ $9,076,000,000.00 |
| Revenue This Year | $30.83 | $11.85 |
| Revenue Next Year | $19.87 | $10.16 |
| P/E Ratio | $170.63 | ★ $34.32 |
| Revenue Growth | ★ 18.79 | 12.49 |
| 52 Week Low | $84.41 | $42.20 |
| 52 Week High | $637.51 | $109.50 |
| Indicator | CIEN | BSX |
|---|---|---|
| Relative Strength Index (RSI) | 59.11 | 70.46 |
| Support Level | $415.37 | $42.32 |
| Resistance Level | $497.90 | $58.35 |
| Average True Range (ATR) | 27.08 | 1.67 |
| MACD | 10.22 | 0.52 |
| Stochastic Oscillator | 95.28 | 86.83 |
Ciena is a leader in high-speed optical connectivity, providing systems, components, and automation software for telecom providers and enterprises, such as data centers, to enable long-distance connectivity. The company operates through four primary business segments: networking platforms, platform software and services, Blue Planet automation software, and global services. While telecom carriers remain important customers, cloud providers and hyperscalers now drive a significant portion of the business. To meet the demands of AI data centers, customers are adopting Ciena's WaveLogic 6 platform, the first to support 1.6 terabits-per-second capacity.
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, kidney stone management, cardiac rhythm management, catheter-directed ultrasound imaging, upper gastrointestinal tract diagnostics, interventional oncology, neuromodulation for chronic pain, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for roughly 36% of the firm's total sales.